Their safety however pleads for further developments, as was demonstrated in three recent phase I clinical trials that tested Epidermal Growth Factor Receptor (EGFR)-targeted minicells loaded with either paclitaxel [62], doxorubicin [63] or miRNA mimics [64] in patients with end-stage solid cancers, glioblastoma or mesothelioma, respectively. This evidence concerns the gene EGFR and mesothelioma.